SWEDISH ORPHAN BIOVITRUM AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 282.4 SEK | +1.66% |
|
+0.79% | +5.77% |
| Sales 2024 * | 24.53B 2.33B 195B | Sales 2025 * | 27.23B 2.59B 216B | Capitalization | 95.98B 9.12B 761B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.41B 324M 27.01B | Net income 2025 * | 4.98B 473M 39.51B | EV / Sales 2024 * | 4.5 x |
| Net Debt 2024 * | 14.54B 1.38B 115B | Net Debt 2025 * | 9.22B 876M 73.07B | EV / Sales 2025 * | 3.86 x |
| P/E ratio 2024 * |
28.3
x | P/E ratio 2025 * |
19.4
x | Employees | 1,752 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Swedish Orphan Biovitrum AB
More press releases
More news
| 1 day | +1.66% | ||
| 1 week | +0.79% | ||
| 1 month | -1.05% | ||
| 3 months | +8.28% | ||
| 6 months | +12.69% | ||
| Current year | +5.77% |
1 week
272.80
283.00
1 month
272.80290.60
Current year
243.20302.00
1 year
197.90302.00
3 years
141.65302.00
5 years
127.10302.00
10 years
65.25302.00
| Managers | Title | Age | Since |
|---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 59 | 22/17/22 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 57 | 20/18/20 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 01/21/01 | |
Annette Clancy
CHM | Chairman | 70 | 08/14/08 |
Staffan Schüberg
BRD | Director/Board Member | 55 | 01/20/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.15% | 232 M€ | +12.88% | ||
| 0.90% | 5 M€ | +15.85% | ||
| 0.69% | 142 M€ | +12.59% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 282.4 | +1.66% | 706,896 |
| 30/24/30 | 277.8 | +1.83% | 254,615 |
| 29/24/29 | 272.8 | -1.09% | 239,560 |
| 28/24/28 | 275.8 | -0.14% | 313,075 |
| 27/24/27 | 276.2 | -1.43% | 136,882 |
Delayed Quote Nasdaq Stockholm, May 31, 2024 at 08:59 pm IST
More quotes
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Companyâs product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
282.4
SEK
Average target price
320
SEK
Spread / Average Target
+13.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.77% | 9.11B | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| -17.66% | 7.32B | |
| +88.73% | 7.14B |
- Stock Market
- Equities
- SOBI Stock
